TG Therapeutics generated $227.7 million in U.S. net product revenue from BRIUMVI during the second quarter of 2026 as adoption of the multiple sclerosis treatment continued expanding.
BRIUMVI revenue increased approximately 64% from $138.8 million during the prior-year quarter.
The treatment also produced sequential growth of roughly 17% from $194.8 million during the first quarter.
Second-quarter BRIUMVI sales exceeded management’s previous target of approximately $220 million by $7.7 million, or about 3.5%.
The commercial performance led TG Therapeutics to raise its full-year BRIUMVI revenue guidance again.
The company had already increased its outlook following the first quarter after stronger demand, record new patient starts, and continued commercial execution exceeded management’s expectations.
Total second-quarter revenue increased approximately 70% to $240.3 million from $141.1 million.
U.S. BRIUMVI sales represented nearly 95% of TG Therapeutics’ total quarterly revenue.
The product generated approximately $86.6 million more revenue than the entire company produced during the second quarter of 2025.
TG recorded approximately $235.8 million of total product revenue during the latest quarter.
The difference between total product revenue and U.S. BRIUMVI sales primarily reflected product supplied to TG’s international commercialization partner.
License, milestone, royalty, and other revenue contributed approximately $4.5 million.
During the first half of 2026, U.S. BRIUMVI revenue reached approximately $422.5 million.
That represents growth of about 63% from $258.5 million during the first half of 2025.
First-half BRIUMVI revenue also equaled approximately 71% of the $594.1 million generated during all of 2025.
Annualizing the second-quarter result would produce a revenue run rate of approximately $911 million.
That calculation is not company guidance and does not account for seasonal trends, changing demand, pricing, inventory movements, or future commercial conditions.
BRIUMVI is approved for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
The treatment is an anti-CD20 monoclonal antibody designed to target CD20-expressing B cells.
Following its initial dosing regimen, BRIUMVI is administered through a one-hour intravenous infusion every 24 weeks.
TG Therapeutics believes the shorter maintenance infusion and twice-yearly schedule help differentiate BRIUMVI within the competitive anti-CD20 treatment market.
The company’s second-quarter growth indicates that BRIUMVI is continuing to gain traction despite competing against established multiple sclerosis treatments.
TG is also working to simplify the intravenous product’s initial dosing schedule.
The Phase 3 ENHANCE trial met its primary endpoint by demonstrating bioequivalent drug exposure between BRIUMVI’s approved Day 1 and Day 15 initiation regimen and a proposed schedule using a single infusion on Day 1.
Safety and tolerability under the consolidated schedule were consistent with BRIUMVI’s established profile.
A simplified starting regimen could reduce the number of initial visits required before patients transition to maintenance dosing every six months.
TG is separately developing a subcutaneous version of BRIUMVI that could allow the company to compete for patients who prefer an injection under the skin rather than an intravenous infusion.
Enrollment has been completed in the randomized Phase 3 program evaluating subcutaneous BRIUMVI.
Topline results are expected around the end of 2026 or during the first quarter of 2027.
TG has budgeted substantial manufacturing, development, and secondary-supplier startup spending for the subcutaneous program.
Those investments reduced near-term profitability even as BRIUMVI revenue increased sharply.
Diluted earnings per share declined to $0.05 from $0.17 during the prior-year quarter as research and development spending increased.
The results demonstrate that TG is using cash generated by the existing intravenous franchise to expand BRIUMVI’s future market opportunity.
A successful subcutaneous formulation could provide an additional administration option and potentially broaden the number of patients and physicians willing to use the product.
TG is also evaluating BRIUMVI in diseases beyond relapsing multiple sclerosis.
The company has initiated development work involving myasthenia gravis, treatment-resistant schizophrenia, and other autoimmune and neurological conditions.
Positive early data in myasthenia gravis supported the initiation of a potentially registration-directed randomized Phase 2 trial.
TG is also developing azer-cel, an allogeneic CAR T-cell therapy, for progressive multiple sclerosis and other autoimmune diseases.
Despite the growing pipeline, BRIUMVI remains the company’s dominant commercial asset and primary source of revenue.
The second-quarter performance shows that the intravenous product is continuing to expand before any contribution from the subcutaneous formulation or additional indications.
Maintaining the current trajectory will depend on continued patient starts, physician adoption, payer coverage, competitive positioning, international expansion, and successful execution across the BRIUMVI development program.
KEY QUOTES:
“Growth is being driven by strong underlying demand, record new patient starts, and consistent commercial execution, reinforcing our belief that we remain early in the adoption curve for BRIUMVI.”
“We continue to see the brand as having multi-billion-dollar potential before considering the impact of a subcutaneous BRIUMVI currently under development.”
Michael S. Weiss, Chairman And Chief Executive Officer Of TG Therapeutics
